Results · Apr-Jun 2026 · filed 6 Aug 2026
Sai Life Sciences Q1 FY27 results
StrongStrong: sales up 10% or more & profit up 20% or more on the same quarter last year, with a wider operating margin.
Sales grew 12% to ₹554 crore from ₹496 crore in Apr-Jun 2025.
Operating profit grew 22% to ₹148 crore, an operating margin of 26.7% (up 2.3 points from a year ago).
Net profit grew 21% to ₹73.3 crore from ₹60.5 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −8%, net profit −30%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 554.3 | 496.4 | +12% |
| Operating profit (EBITDA) | 148.0 | 120.9 | +22% |
| Operating margin | 26.7% | 24.4% | +2.3 pts |
| Net profit | 73.3 | 60.5 | +21% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Sai Life Sciences reported Apr–Jun 2026 revenue of ₹553 crore, up 12% from a year earlier, with CRO growing 26% & CDMO growing 6%. Management expects Oct 2026 to Mar 2027 to be stronger than H1 due to capacity coming online & remains confident in 15-20% medium-term growth guidance.
The last 7 quarters
Filings that week
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- 8 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 6 Aug 2026Announcement under Regulation 30 (LODR)-Allotment
- 6 Aug 2026Press Release For The Unaudited Financial Results For The Quarter Ended On June 30, 2026
- 6 Aug 2026Considered And Approved Unaudited Financial Results For The Quarter Ended On 30 June, 2026.
- 6 Aug 2026Board Meeting Outcome for Considered And Approved The Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended On 30 June 2026
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.